Two men share securities regulation news

Breaking news and expert analysis on legal and compliance issues

[Back To Home][Back To Archives]

From Securities Regulation Daily, March 24, 2016

Novartis subsidiaries bribed Chinese officials to increase sales

By Amanda Maine, J.D.

Novartis AG has agreed to pay $25 million in disgorgement and penalties for violating the Foreign Corrupt Practices Act (FCPA). Employees and agents of Chinese subsidiaries of the Switzerland-headquartered pharmaceutical company allegedly provided cash and gifts to government officials in China in connection with its pharmaceutical sales (In the Matter of Novartis AG, Release No. 34-77431, March 23, 2016).

Payments. The SEC alleged that employees of a Novartis Shanghai subsidiary provided gifts, travel, improper sightseeing and vacations, and family favors to Chinese officials, principally healthcare professionals (HCPs). Employees and agents of Novartis’ Beijing subsidiary also made payments to Chinese government officials. These payments were intended to influence HCPs and increase sales of Novartis pharmaceutical products.

The Novartis subsidiaries improperly recorded the payments to the HCPs as legitimate expenses, according to the SEC. The illicit payments were recorded on the general ledger as employee expenses, sponsorships, conferences, medical studies, and marketing costs.

Novartis review. Novartis instituted a review of its Chinese subsidiaries in connection with an SEC investigation and media reports about a competitor in 2013. The review showed that events funded by Novartis for HCPs did not comply with Novartis’s policies and procedures, including maintaining inconsistent records and non-verifiable events. As a result of the review, Novartis was able to identify weaknesses in its internal controls over third-party relationships in China.

Charges and sanctions. The SEC charged Novartis with violating the books and records and internal controls provisions of the FCPA. Without admitting or denying the SEC’s allegations, Novartis agreed to pay disgorgement plus prejudgment interest of $23 million and a civil monetary penalty of $2 million. It also agreed to cease and desist from future violations.

As part of the settlement, Novartis agreed to a series of undertakings, including reporting to the Commission regarding its FCPA compliance program and performing follow-up reviews of its efforts to improve its compliance policies. The SEC noted in its order instituting administrative proceedings that Novartis has already taken remedial steps to improve internal controls at its Chinese subsidiaries, including terminating culpable employees, suspending certain vendor relationships, increasing its training initiatives, and reorganizing its compliance program to include enhanced oversight by regional and headquarter personnel.

The release is No. 34-77431.

Companies: Novartis AG; Shanghai Novartis Trading Ltd.; Beijing Novartis Pharma Co., Ltd.

MainStory: TopStory Enforcement AccountingAuditing InternationalNews

Back to Top

Securities Regulation Daily

Introducing Wolters Kluwer Securities Regulation Daily — a daily reporting service created by attorneys, for attorneys — providing same-day coverage of breaking news, court decisions, legislation, and regulatory activity.

A complete daily report of the news that affects your world

  • View full summaries of federal and state court decisions.
  • Access full text of legislative and regulatory developments.
  • Customize your daily email by topic and/or jurisdiction.
  • Search archives for stories of interest.

Not just news — the right news

  • Get expert analysis written by subject matter specialists—created by attorneys for attorneys.
  • Track law firms and organizations in the headlines with our new “Who’s in the News” feature.
  • Promote your firm with our new reprint policy.

24/7 access for a 24/7 world

  • Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues.
  • Save time with mobile apps for your BlackBerry, iPhone, iPad, Android, or Kindle.
  • Access all links from any mobile device without being prompted for user name and password.